Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor ...
2-Year U.S. Treasury Note Continuous Contract $104.211 0.008 0.01% 5-Year U.S. Treasury Note Continuous Contract $108.859-0.023-0.02% 10-Year U.S. Treasury Note Continuous Contract $111.734-0.125-0.11 ...
Petroleo Brasileiro S/A Ord 0.34% R$469.5B Petroleo Brasileiro S/A Pref 0.91% R$469.5B Go to the homepage.
There is no recent news for this security. Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more CNBC delivered to your inbox Get this delivered to your ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results